References
- Ulver I N, Schwarz M A. Use of dimethyl sulfoxide in limiting tissue damage caused by extravasation of doxorubicin. Cancer Treat Rep 1983; 67: 407–8
- Minow A M, Benjamin R S, Lee E T, Gottlieb J A. Adriamycin cardiomyopathy—Risk factors. Cancer 1977; 39: 1397–402
- VonHoff D D, Layard M W, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7
- Henderson J C, Frei E. Adriamycin cardiotoxicity—Correspondence. Am Heart J 1980; 99: 671–4
- Eksborg S, Hardell L, Bengtsson N O, Sjödin M, Elfsson D. Epirubicin as a single agent therapy for the treatment of breast cancer—a pharmacokinetic and clinical study. Med Oncol Tumor Pharmacother 1992; 9: 75–80
- Neri B, Pacini P, Algeri R, et al. Conventional versus high-dose epidoxorubicin as single agent in advanced breast cancer. Cancer Invest 1993; 11: 106–12
- Vermorken J B, Zanaboni F, Kobierska A, et al. Phase II study of high-dose epirubicin (HDE) in patients with ovarian carcinoma (OC) previously treated with cisplatin (P). Ann Oncol 1992; 3: 104
- Rosen G, Caparros P, Huvos A G, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221–30
- Weiss A J, Manthel R W. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule with particular reference to the lack of cardiac toxicity. Cancer 1977; 40: 2046–52
- Taylor A L, Applefeld M M, Wiernik P H, Grochow L B, Mader L C, Bulkley B H. Acute anthracycline cardiotoxicity. Cancer 1984; 53: 1660–6
- Pelikan P CD, Weisfeldt M L, Jacobus W E, Miceli M V, Bulkley B H, Gerstenblith G. Acute doxorubicin toxicity: Functional, metabolic and morphologic alterations in the isolated, perfused rat heart. J Cardiovasc Pharmacol 1986; 8: 1058–66
- Steinberg J S, Cohen A J, Wasserman A G, Cohen P, Ross A M. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60: 1213–8
- Wortman J E, Lucas V S, Schuster E, Thiele O, Logue G L. Sudden death during doxorubicin administration. Cancer 1979; 44: 1588–91
- Zulian G B. Acute toxicity of epirubicin—Correspondence. J Clin Oncol 1986; 4: 1867–8
- Hachimi-Idrissi S, Schots R, Dewolf D, Van Belle S JP, Otten J. Reversible cardiopathy after accidental overdose of mitoxantrone. Pediatr Hematol Oncol 1993; 10: 35–40
- Mortensen M E, Cecalupo A J, Egorin M J, Batley R. Inadvertent intrathecal injection of daunorubicin with fatal outcome. Med Pediatr Oncol 1992; 20: 249–53
- Eksborg S, Strander H S, Edsmyr F, Näslund I, Tahvanainen P. Pharmacokinetic study of IV infusions of adriamycin. Eur J Clin Pharmacol 1985; 28: 205–12
- Eksborg S, Ehrsson H, Andersson I. Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol. J Chromatogr 1979; 164: 479–86